ReviewClinical pharmacokinetics2019
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.
Erratum issued 2 registry-linked trialsAbstract readReview
In one paragraph
Review in Clinical pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Biomarker Study in Active Secondary Progressive Multiple Sclerosis (SPMS)Subjects Treated With Cladribine Tablets
Importance of Therapeutic Monitoring of Orally Administered Disease-modifying Drugs Used in the Treatment of Multiple Sclerosis
Who cites it
35 citing papers in PubMed.
- Effect of Cladribine Tablets on the Pharmacokinetics of a Combined Oral Contraceptive in Pre-Menopausal Women With Relapsing Multiple Sclerosis.Clinical and translational science · 2025Trial
- Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.British journal of clinical pharmacology · 2019Trial
- A drug evaluation narrative review of cladribine as a treatment for multiple sclerosis.Neurodegenerative disease management · 2025Review
- Cladribine Preserves Normal Central Nervous System Cellular Activity and Promotes Neuroprotection to Oxidative Stress Damage.International journal of molecular sciences · 2025Article
- Cyclodextrin Complexes for Clinical Translatability: Applications for Cladribine and Retrometabolically Designed Estredox.International journal of molecular sciences · 2025Review
- Effects of cladribine on intrathecal and peripheral B and plasma cells.Clinical and experimental immunology · 2025Article
- A computational approach to drug design for multiple sclerosis via QSPR modeling, chemical graph theory, and multi-criteria decision analysis.BMC chemistry · 2025Article
- Cladribine tablets in the new multiple sclerosis era.Therapeutic advances in neurological disorders · 2025Review
- Chemokines as therapeutic targets for multiple sclerosis: a spatial and chronological perspective.Frontiers in immunology · 2025Review
- Towards Treating Multiple Sclerosis Progression.Pharmaceuticals (Basel, Switzerland) · 2024Review
- CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis.Frontiers in immunology · 2024Article
- Cultured lymphocytes' mitochondrial genome integrity is not altered by cladribine.Clinical and experimental immunology · 2023Article
- Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients.Brain sciences · 2022Article
- Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitis.Journal of neuroinflammation · 2022Article
- Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?CNS drugs · 2022Review
- Predicting disease activity in patients with multiple sclerosis: An explainable machine-learning approach in the Mavenclad trials.CPT: pharmacometrics & systems pharmacology · 2022Article
- Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.Neurology and therapy · 2022Review
- Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2022Article
- Model-informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets.Clinical and translational science · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Robert HermannClinical Research Appliance (Cr Appliance), Heinrich-Vingerhut-Weg 3, 63571, Gelnhausen, Germany. robert.hermann@cr-appliance.com.
Mats O KarlssonDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Ana M NovakovicMerck KGaA, Darmstadt, Germany.
Nadia TerranovaMerck Institute for Pharmacometrics, Merck Serono S.A., Switzerland, an Affiliate of Merck KGaA, Darmstadt, Germany.
Markus FluckMerck KGaA, Darmstadt, Germany.
Alain MunafoMerck Institute for Pharmacometrics, Merck Serono S.A., Switzerland, an Affiliate of Merck KGaA, Darmstadt, Germany.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cladribine Tablets (MAVENCLAD
Indexed as
Administration, OralAdultAgedATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily G, Member 2Biological AvailabilityCladribineCytochrome P-450 Enzyme SystemEquilibrative Nucleoside Transporter 1FemaleHumansImmunosuppressive AgentsLymphocytesMaleMembrane Transport ProteinsMiddle AgedABCG2 protein, humanATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily G, Member 2cif nucleoside transporterCladribineCytochrome P-450 Enzyme SystemEquilibrative Nucleoside Transporter 1Immunosuppressive AgentsMembrane Transport ProteinsNeoplasm Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT04550455ClinicalTrials.gov
NCT05112484ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.